<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03530267</url>
  </required_header>
  <id_info>
    <org_study_id>ELDERLY</org_study_id>
    <nct_id>NCT03530267</nct_id>
  </id_info>
  <brief_title>Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer</brief_title>
  <acronym>ELDERLY</acronym>
  <official_title>Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>STABIL - Statistische und Biometrische Lösungen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trium Analysis Online GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a controlled, open-label, randomized phase- II trial (1:1 randomization)
      investigating 5-FU + aflibercept and 5-FU + oxaliplatin in elderly and frail elderly patients
      with mCRC scheduled to receive first line treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current trial seeks to evaluate a new treatment option for elderly / frail elderly
      patients with mCRC including 5-FU - better tolerated than capecitabine in the FOCUS2 study -
      in conjunction with aflibercept, a broad active anti-angiogenic drug within a randomized
      phase-II setting. Patients will be randomized using a 1:1 randomization between 5-FU /
      aflibercept and 5-FU / oxaliplatin using the oxaliplatin-based regimen established in FOCUS2
      trial. Main goal is to estimate the 6-months PFS rate with 5-FU / Aflibercept and the safety
      of this regimen. The decision to use a randomized phase-II design using the &quot;FOCUS2- FOLFOX&quot;
      is based on two assumptions; (i) Bias can be better controlled by using a randomized phase-II
      design (ii) A clear standard regimen in frail elderly cannot be defined, but FOLFOX was
      superior to 5-FU alone in FOCUS2 and the patient population included in the FOCUS2 study
      represents the patient population scheduled to be included in the current trial.

      Provided the randomized phase-II study shows adequate efficacy of 5-FU / aflibercept and a
      tolerable safety profile, the study will be carried on to the phase-III part of the trial.
      Description of the terms and conditions to expand the current trial are not part of this
      protocol. Briefly, a potential phase-III study should aim at showing non-inferiority of 5-FU
      / aflibercept regarding 6-months PFS rate as primary endpoint. This would allow to include
      all patients from the phase-II part in the phase-III study in order to save time and
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2018</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of patients free of progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Dose intensities of study medication</measure>
    <time_frame>6 months</time_frame>
    <description>As calculated over the whole treatment duration and summarized descriptively by summary statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse events (AE)</measure>
    <time_frame>7 months</time_frame>
    <description>AE's will be summarized by presenting the number and percentages of patients having any AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Dose modification of study drug due to adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Dose modifications, including discontinuations, will be summarized by presenting the number and percentages of patients having any dose modification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Rate of treatment discontinuation due to toxicitiy</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of treatment discontinuations during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Laboratory abnormalities</measure>
    <time_frame>6 months</time_frame>
    <description>Summary of lab abnormalities as assessed in the documentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Response rates</measure>
    <time_frame>2 years</time_frame>
    <description>As measured by RECIST criteria v. 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>OS according to Kaplan-Meier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: PFS</measure>
    <time_frame>2 years</time_frame>
    <description>PFS according to Kaplan-Meier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes (PRO): Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life (QoL) as measured by EQ-5D-5L at d1 of each cycle and on EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRO: Geriatric assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Geriatric assessment as measured by using G8, ADL and IADL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRO: Overall treatment utility</measure>
    <time_frame>6 months</time_frame>
    <description>Overall treatment utility is evaluated according to the principles used in the FOCUS2 trial. Cf. Seymour et al. Geriatric oncol 2013.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (mFOLFOX7)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the 5-FU / oxaliplatin arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
This regimen represents the 80% dosage reduced mFOLFOX 7. The 80% dose reduction was shown to be a tolerable regimen in frail elderly patients in the FOCUS 2 study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Aflibercept + mLV5FU2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the 5-FU / aflibercept arm receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
The decision to use reduced doses of 5-FU and folinic acid was made to have comparable doses to the reduced FOLFOX 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept + mLV5FU2</intervention_name>
    <description>Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).</description>
    <arm_group_label>Arm B (Aflibercept + mLV5FU2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX7</intervention_name>
    <description>Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).</description>
    <arm_group_label>Arm A (mFOLFOX7)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. To enter this trial the oncologist has to confirm, that the patient was in his or her
             opinion not a candidate for standard full-dose combination therapy. Moreover, the
             oncologist has to state the reason for entering the trial (Advanced age alone versus
             both age and frailty). As an operational definition for frailty the G8 screening tool
             will be used upon inclusion of the patient in a standardized manner. Briefly, G8 is an
             established screening tool that includes seven items from the Mini Nutritional
             Assessment (MNA) and an age-related item (&lt;80, 80 to 85, or 85 years). The total score
             can range from 0 to 17. The result on the G8 is considered abnormal if the score is
             ≤14, indicating a geriatric risk profile.

          2. Patients have to have histologically confirmed mCRC with unidimensionally measurable
             inoperable advanced or metastatic disease

          3. ECOG performance status of 2 or better.

          4. Life expectancy of 3 months or longer at enrolment

          5. Patients &gt;70 years with no upper age limit

          6. Previous adjuvant chemotherapy is allowed if completed more than 6 months before
             randomisation

          7. Previous rectal (chemo)radiotherapy is allowed if completed more than 6 months before
             randomisation

          8. Hematological status:

               -  Neutrophils (ANC) ≥ 1.5 x 109/L

               -  Platelets ≥ 100 x 109/L

               -  Hemoglobin ≥ 9 g/dL

          9. Adequate renal function:

             • Serum creatinine level ≤ 1.5 x upper limit normal (ULN)

         10. Adequate liver function:

               -  Serum bilirubin ≤ 1.5 x upper limit normal (ULN)

               -  Alkaline phosphatase ≤ 2.5 x ULN (unless liver metastases are present, then &lt; 5 x
                  ULN in that case)

               -  AST and ALT &lt; 3 x ULN (unless liver metastases are present then &lt; 5 x ULN in that
                  case)

         11. Proteinuria &lt; 2+ (dipstick urinalysis) or ≤ 1 g/24hour

         12. Signed and dated informed consent, and willing and able to comply with protocol
             requirements

         13. Regular follow-up feasible

         14. Male patients with a partner of childbearing potential must agree to use effective
             contraception (Pearl Index &lt; 1) during the course of the trial and at least 3 months
             after last administration of the study drug.

        Exclusion Criteria:

          1. Prior systemic chemotherapy for mCRC

          2. Other concomitant or previous malignancy, except:

               -  Adequately treated in-situ carcinoma of the uterine cervix

               -  Basal or squamous cell carcinoma of the skin

               -  Cancer in complete remission for &gt; 5 years

          3. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic
             injury within the last 28 Days

          4. History or evidence upon physical examination of CNS metastasis unless adequately
             treated (irradiation and no seizure with appropriate treatment)

          5. Uncontrolled hypercalcemia

          6. Pre-existing peripheral neuropathy (NCI grade ≥2)

          7. Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular
             targeted therapy, immunotherapy),

          8. Treatment with any other investigational medicinal product within 28 days prior to
             study entry.

          9. Significant cardiovascular disease:

               -  Cardiovascular accident or myocardial infarction or unstable angina ≤6 months
                  before start of study treatment

               -  Severe cardiac arrhythmia

               -  New York Heart Association grade ≥2 congestive heart failure

               -  Uncontrolled hypertension (defined as systolic blood pressure &gt;150 mmHg and/or
                  diastolic blood pressure &gt;100 mmHg), or history of hypertensive crisis, or
                  hypertensive encephalopathy.

               -  History of stroke or transient ischemic attack ≤6 months before start of study
                  treatment

               -  Coronary/peripheral artery bypass graft ≤6 months before start of study
                  treatment.

               -  Deep vein thrombosis or thromboembolic events ≤1 month before start of study
                  treatment

         10. Patients with known allergy to any excipient to study drugs,

         11. Any of the following within 3 months prior to randomization: Grade 3-4
             gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease,
             erosive oesophagitis or gastritis, infectious or inflammatory bowel disease,
             diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event.

         12. Bowel obstruction.

         13. Treatment with CYP3A4 inducers unless discontinued &gt; 7 days prior to randomization

         14. Known dihydropyrimidine dehydrogenase (DPD) deficiency

         15. Involvement in the planning and/or conduct of the study (applies to both Sanofi staff
             and/or staff of sponsor and study site)

         16. Patient who might be dependent on the sponsor, site or the investigator

         17. Patient who has been incarcerated or involuntarily institutionalized by court order or
             by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.

         18. Patients who are unable to consent because they do not understand the nature,
             significance and implications of the clinical trial and therefore cannot form a
             rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf-Dieter Hofheinz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Mannheim, Tagestherapiezentrum am ITM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salah-Eddin Al-Batran, Prof. Dr.</last_name>
    <phone>+49697601</phone>
    <phone_ext>4420</phone_ext>
    <email>albatran@ikf-khnw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerrit zur Hausen, Dr.</last_name>
    <phone>+49697601</phone>
    <phone_ext>4518</phone_ext>
    <email>zurhausen.gerrit@ikf-khnw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phase Drei</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manfred Welslau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Kiani, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Seestrasse</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen Nord</name>
      <address>
        <city>Bremen</city>
        <zip>28755</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruben R. Plentz, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Stahl, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Bolling, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Garmisch-Partenkirchen GmbH</name>
      <address>
        <city>Garmisch-Partenkirchen</city>
        <zip>82467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Till Seiler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen (NCT)</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Berger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margarethe Schmier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DRK-Kliniken Nordhessen gGmbH</name>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathias Kleiss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum Lahr</name>
      <address>
        <city>Lahr</city>
        <zip>77933</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Egger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologisches Zentrum</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Bauer, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralf Jakobs, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg gGmbH</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Kahl, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tagestherapiezentrum am ITM Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Ostalb</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Holger Hebart, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München-Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken des Landkreises Neumarkt in der Oberpfalz</name>
      <address>
        <city>Neumarkt In Der Oberpfalz</city>
        <zip>92318</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Horndasch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Stolberg GmbH</name>
      <address>
        <city>Stolberg</city>
        <zip>52222</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Groschek</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus Trier</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rolf Mahlberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans-Georg Kopp, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Wilhelmshaven</name>
      <address>
        <city>Wilhelmshaven</city>
        <zip>26389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE; FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011 May 21;377(9779):1749-59. doi: 10.1016/S0140-6736(11)60399-1. Epub 2011 May 11.</citation>
    <PMID>21570111</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>5-FU</keyword>
  <keyword>Aflibercept</keyword>
  <keyword>Oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

